{"protocolSection": {"identificationModule": {"nctId": "NCT00715624", "orgStudyIdInfo": {"id": "EFC6016"}, "secondaryIdInfos": [{"id": "2007-005886-36", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin", "acronym": "GETGOAL-L"}, "statusModule": {"statusVerifiedDate": "2016-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-07"}, "primaryCompletionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-07-11", "studyFirstSubmitQcDate": "2008-07-11", "studyFirstPostDateStruct": {"date": "2008-07-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-08-18", "resultsFirstSubmitQcDate": "2016-08-18", "resultsFirstPostDateStruct": {"date": "2016-10-11", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-02-21", "dispFirstSubmitQcDate": "2012-02-21", "dispFirstPostDateStruct": {"date": "2012-02-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-10-14", "lastUpdatePostDateStruct": {"date": "2016-11-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide when added to basal insulin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction at Week 24.\n\nThe secondary objectives are to assess the effects of lixisenatide when added to basal insulin on body weight, 2-hour postprandial plasma glucose (PPG) after standardized meal challenge test, percentage of patients reaching HbA1c less than 7 percent (%), percentage of patients reaching HbA1c less than or equal to 6.5%, fasting plasma glucose (FPG), change in 7-point self-monitored plasma glucose (SMPG) profiles, change in basal insulin and total insulin doses; to evaluate safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.", "detailedDescription": "Patients who complete the 24-week main double-blind treatment would undergo a variable double-blind extension treatment, which ends for all patients at approximately the scheduled date of Week 76 visit (Visit 25) for the last randomized patients."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["hyperglycemia, GLP-1, metformin, insulin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 496, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lixisenatide", "type": "EXPERIMENTAL", "description": "2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.", "interventionNames": ["Drug: Lixisenatide (AVE0010)", "Drug: Basal Insulin", "Drug: Metformin", "Device: Pen auto-injector"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.", "interventionNames": ["Drug: Placebo", "Drug: Basal Insulin", "Drug: Metformin", "Device: Pen auto-injector"]}], "interventions": [{"type": "DRUG", "name": "Lixisenatide (AVE0010)", "description": "Self administered by subcutaneous injections once daily within the hour preceding breakfast.", "armGroupLabels": ["Lixisenatide"]}, {"type": "DRUG", "name": "Placebo", "description": "Self administered by subcutaneous injections once daily within the hour preceding breakfast.", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Basal Insulin", "description": "Dose to be kept stable.", "armGroupLabels": ["Lixisenatide", "Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.", "armGroupLabels": ["Lixisenatide", "Placebo"]}, {"type": "DEVICE", "name": "Pen auto-injector", "armGroupLabels": ["Lixisenatide", "Placebo"], "otherNames": ["OptiClik\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profiles at Week 24", "description": "Patients recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime once in a week and the average value for the 7-time points was calculated. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Total Insulin Dose at Week 24", "description": "Change was calculated for total insulin dose by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period", "description": "Routine fasting SMPG and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\> 8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline up to Week 24"}], "otherOutcomes": [{"measure": "Change From Baseline in Glucose Excursion at Week 24", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "timeFrame": "First dose of study drug up to 3 days after the last dose administration for up to 125 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with basal insulin with or without metformin\n\nExclusion Criteria:\n\n* HbA1c less than (\\<) 7 % or greater than (\\>) 10% at screening\n* At the time of screening age \\< legal age of majority\n* Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method\n* Type 1 diabetes mellitus\n* Treatment with basal insulin for less than 3 months prior to screening or insulin regimen changed during the last 3 months prior to screening\n* Basal insulin dose at screening \\<30 units/day and/or not at a stable dose (+/- 20 percent \\[%\\]) during the last 2 months\n* If treatment with metformin, no stable dose of at least 1.5 gram/day (except for South Korea: at least 1.0 gram/day) for at least 3 months prior to screening visit\n* FPG at screening \\>250 milligram per deciliter (mg/dL) (\\>13.9 millimole per liter \\[mmol/L\\])\n* History of hypoglycemia unawareness\n* Body mass index less than or equal to (\\<=) 20 kilogram per square meter (kg/m\\^2)\n* Weight change of \\>5 kg during the 3 months preceding the screening visit\n* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, or inflammatory bowel disease\n* History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening\n* Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening\n* Within the last 6 months prior to screening, history of myocardial infarction, stroke, or heart failure requiring hospitalization\n* Known history of drug or alcohol abuse within 6 months prior to the time of screening\n* Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period\n* Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure (SBP) or diastolic blood pressure (DBP) \\>180 millimeter of mercury (mmHg) or \\>95 mmHg, respectively\n* Laboratory findings at the time of screening: aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase: \\>2 times upper limit of the normal (ULN) laboratory range; amylase and/or lipase: \\>3 times ULN; total bilirubin: \\>1.5 times ULN (except in case of Gilbert's syndrome); hemoglobin \\<11 gram/deciliter and/or neutrophils \\<1500 per cubic millimeter (mm\\^3) and/or platelets \\<100 000/mm\\^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody and positive serum pregnancy test in females of childbearing potential\n* Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram, or vital signs at the time of screening that, in the judgment of the investigator or any sub-investigator, precludes safe completion of the study or constrains efficacy assessment\n* Patients who are considered by the investigator or any sub-investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as attending scheduled visits, being able to do self-injections; likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol; investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol)\n* Use of other oral or injectable antidiabetic or hypoglycemic agents other than metformin or basal insulin (for example, sulfonylurea, alpha-glucosidase inhibitor, thiazolidinedione, rimonabant, exenatide, dipeptidyl-peptidase-4 inhibitors, fast-acting insulin for 1 week or more) within 3 months prior to the time of screening\n* Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to the time of screening\n* Any previous treatment with lixisenatide or participation in any previous study with lixisenatide\n* Use of any investigational drug within 3 months prior to study\n* Renal impairment defined with creatinine \\>1.4 mg/dL in women and creatinine \\>1.5 mg/dL in men (applicable only for patients with metformin treatment)\n* End-stage renal disease as defined by a calculated serum creatinine clearance of \\<15 milliliter/minute and/or patients on dialysis, if no treatment with metformin\n* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment, within the previous 6 months\n* History of allergic reaction to any glucagon like peptide-1 (GLP-1) agonist in the past (for example, exenatide, liraglutide) or to metacresol\n* Additional exclusion criteria at the end of the run-in phase: informed consent withdrawal; lack of compliance during the single-blind placebo run-in phase (\\>2 injections missed); and patient with any adverse event which precludes the inclusion in the study, as assessed by the investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sanofi-Aventis Administrative Office", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Laval", "country": "Canada", "geoPoint": {"lat": 45.56995, "lon": -73.692}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Cairo", "country": "Egypt", "geoPoint": {"lat": 30.06263, "lon": 31.24967}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Mumbai", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Milano", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Puerto Rico", "country": "Puerto Rico"}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Guildford Surrey", "country": "United Kingdom", "geoPoint": {"lat": 51.23536, "lon": -0.57427}}]}, "referencesModule": {"references": [{"pmid": "23628617", "type": "RESULT", "citation": "Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013 Sep;36(9):2489-96. doi: 10.2337/dc12-2454. Epub 2013 Apr 29."}, {"pmid": "31956422", "type": "DERIVED", "citation": "Davidson JA, Stager W, Paranjape S, Berria R, Leiter LA. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. Clin Diabetes Endocrinol. 2020 Jan 14;6:2. doi: 10.1186/s40842-019-0088-5. eCollection 2020."}, {"pmid": "25130920", "type": "DERIVED", "citation": "Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications. 2014 Nov-Dec;28(6):880-6. doi: 10.1016/j.jdiacomp.2014.07.007. Epub 2014 Jul 18."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 879 patients were screened of which 383 (43.6%) were screen failures; main reason for screen failure was glycosylated hemoglobin (HbA1c) values being out of the defined protocol range (greater than or equal to 7% and less than or equal to 10%). A total of 496 patients were randomized.", "recruitmentDetails": "The study was conducted at 111 centers in 15 countries between July 29, 2008 and February 8, 2011. The overall duration of treatment was at least 76 weeks (24 weeks main double-blind treatment; variable double-blind extension treatment).", "groups": [{"id": "FG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "FG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized", "numSubjects": "167"}, {"groupId": "FG001", "numSubjects": "329"}]}, {"type": "Treated/Safety Population", "achievements": [{"groupId": "FG000", "comment": "All patients who were exposed to at least 1 dose, regardless of amount of treatment administered.", "numSubjects": "167"}, {"groupId": "FG001", "numSubjects": "328"}]}, {"type": "Modified Intent-to-Treat(mITT)Population", "achievements": [{"groupId": "FG000", "comment": "All patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment.", "numSubjects": "166"}, {"groupId": "FG001", "numSubjects": "327"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "115"}, {"groupId": "FG001", "numSubjects": "213"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "52"}, {"groupId": "FG001", "numSubjects": "116"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "37"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "Familial and personal reasons", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "Poor compliance", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Sponsor decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Incorrect randomization (not treated)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.", "groups": [{"id": "BG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "BG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "167"}, {"groupId": "BG001", "value": "328"}, {"groupId": "BG002", "value": "495"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.9", "spread": "9.8"}, {"groupId": "BG001", "value": "57.4", "spread": "9.5"}, {"groupId": "BG002", "value": "57.2", "spread": "9.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "182"}, {"groupId": "BG002", "value": "267"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "146"}, {"groupId": "BG002", "value": "228"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Race: Caucasian/White", "categories": [{"measurements": [{"groupId": "BG000", "value": "130"}, {"groupId": "BG001", "value": "254"}, {"groupId": "BG002", "value": "384"}]}]}, {"title": "Race: Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "20"}]}]}, {"title": "Race: Asian/Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "83"}]}]}, {"title": "Race: Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "Ethnicity: Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "134"}]}]}, {"title": "Ethnicity: Non Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "234"}, {"groupId": "BG002", "value": "361"}]}]}]}, {"title": "Glycosylated Hemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.37", "spread": "0.84"}, {"groupId": "BG001", "value": "8.42", "spread": "0.88"}, {"groupId": "BG002", "value": "8.40", "spread": "0.87"}]}]}]}, {"title": "2-Hour Postprandial Plasma Glucose (PPG)", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Number of patients analyzed = 153 and 302 for Placebo and Lixisenatide treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.11", "spread": "3.86"}, {"groupId": "BG001", "value": "16.47", "spread": "4.30"}, {"groupId": "BG002", "value": "16.35", "spread": "4.15"}]}]}]}, {"title": "Average 7-Point Self Monitored Plasma Glucose (SMPG)", "description": "Patients recorded a 7-point plasma glucose profile before and 2 hours after each meal and at bedtime once in a week and the average value for the 7-time points was calculated. Number of patients analyzed = 155 and 301 for Placebo and Lixisenatide treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.58", "spread": "2.69"}, {"groupId": "BG001", "value": "10.76", "spread": "2.61"}, {"groupId": "BG002", "value": "10.70", "spread": "2.64"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "millimole per liter (mmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.05", "spread": "2.65"}, {"groupId": "BG001", "value": "8.13", "spread": "2.83"}, {"groupId": "BG002", "value": "8.10", "spread": "2.76"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "88.94", "spread": "20.84"}, {"groupId": "BG001", "value": "87.10", "spread": "20.01"}, {"groupId": "BG002", "value": "87.72", "spread": "20.29"}]}]}]}, {"title": "Total Insulin Dose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units per day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.73", "spread": "34.54"}, {"groupId": "BG001", "value": "53.43", "spread": "33.89"}, {"groupId": "BG002", "value": "54.88", "spread": "34.14"}]}]}]}, {"title": "Glucose Excursion", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the meal test, before study drug administration. Number of patients analyzed = 153 and 301 for Placebo and Lixisenatide treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.32", "spread": "3.43"}, {"groupId": "BG001", "value": "7.59", "spread": "3.60"}, {"groupId": "BG002", "value": "7.50", "spread": "3.54"}]}]}]}, {"title": "Duration of Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12.43", "spread": "6.33"}, {"groupId": "BG001", "value": "12.48", "spread": "7.04"}, {"groupId": "BG002", "value": "12.46", "spread": "6.80"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "BMI was calculated by dividing body weight by the height squared.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram per square meter (kg/m^2)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.56", "spread": "6.32"}, {"groupId": "BG001", "value": "31.91", "spread": "6.17"}, {"groupId": "BG002", "value": "32.13", "spread": "6.22"}]}]}]}, {"title": "Basal Insulin Treatment Duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.20", "spread": "3.96"}, {"groupId": "BG001", "value": "3.06", "spread": "3.37"}, {"groupId": "BG002", "value": "3.11", "spread": "3.57"}]}]}]}, {"title": "Number of Patients With Insulin Therapy at Baseline", "description": "NPH included isophane insulin and insulin human injection, isophane. Premix insulin included Novolin 70/30 mix and Humalog 75/25 mix.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Glargine", "categories": [{"measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "165"}, {"groupId": "BG002", "value": "248"}]}]}, {"title": "Detemir", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "43"}]}]}, {"title": "Neutral protamine hagedorn (NPH)", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "134"}, {"groupId": "BG002", "value": "198"}]}]}, {"title": "Premix (Mixed Insulin)", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Number of Patients With Metformin use at Baseline", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "261"}, {"groupId": "BG002", "value": "392"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "103"}]}]}]}, {"title": "Metformin Daily Dose", "description": "Here, number of patients analyzed = 131 and 261 for Placebo and Lixisenatide treatment arm, respectively as only these participants received metformin.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "milligram (mg) per day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2008.02", "spread": "441.88"}, {"groupId": "BG001", "value": "1961.02", "spread": "459.07"}, {"groupId": "BG002", "value": "1976.72", "spread": "453.38"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. LOCF was used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of hemoglobin", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "304"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "0.107"}, {"groupId": "OG001", "value": "-0.74", "spread": "0.090"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To detect a difference of 0.5% (or 0.4%) in change from baseline to Week 24 in HbA1c between lixisenatide and placebo, 300 patients in lixisenatide arm and 150 in placebo arm would provide a power of 96% (or 86%) assuming common standard deviation of 1.3% with a 2-sided test at 5% significance level.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "pValueComment": "Statistical testing: 2-sided at significance level=0.05. Analysis of co-variance (ANCOVA) included treatment arms, randomization strata of screening HbA1c (\\<8.0, \\>=8.0%), metformin use (yes, no), country as fixed effects, baseline HbA1c as covariate.", "statisticalMethod": "ANCOVA", "statisticalComment": "To control type I error, a step-down procedure described by Hochberg and Tomhane was applied.", "paramType": "Least squares (LS) mean difference", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.550", "ciUpperLimit": "-0.174", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.096"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline 2-hour PPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "235"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.72", "spread": "0.543"}, {"groupId": "OG001", "value": "-5.54", "spread": "0.468"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profiles at Week 24", "description": "Patients recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime once in a week and the average value for the 7-time points was calculated. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline 7-point SMPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "294"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.61", "spread": "0.238"}, {"groupId": "OG001", "value": "-1.49", "spread": "0.201"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "317"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "0.281"}, {"groupId": "OG001", "value": "-0.63", "spread": "0.233"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilogram", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "311"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.52", "spread": "0.293"}, {"groupId": "OG001", "value": "-1.80", "spread": "0.246"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Insulin Dose at Week 24", "description": "Change was calculated for total insulin dose by subtracting the baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline total insulin dose assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units per day", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}, {"groupId": "OG001", "value": "325"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.93", "spread": "1.589"}, {"groupId": "OG001", "value": "-5.62", "spread": "1.317"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "304"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.0"}, {"groupId": "OG001", "value": "28.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "304"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.8"}, {"groupId": "OG001", "value": "14.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period", "description": "Routine fasting SMPG and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\> 8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "166"}, {"groupId": "OG001", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.2"}, {"groupId": "OG001", "value": "5.8"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Glucose Excursion at Week 24", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucose excursion assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.34", "spread": "0.469"}, {"groupId": "OG001", "value": "-4.14", "spread": "0.408"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "311"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.1"}, {"groupId": "OG001", "value": "13.2"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "populationDescription": "Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "First dose of study drug up to 3 days after the last dose administration for up to 125 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "328"}]}], "classes": [{"title": "Symptomatic hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "138"}]}]}, {"title": "Severe symptomatic hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "First dose of study drug up to 3 days after the last dose administration for up to 125 weeks", "description": "Median exposure to study treatment was 560 and 559 days in lixisenatide and placebo treatment arms, respectively. The analysis was performed on safety population, defined as all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "2-step initiation regimen of volume matching placebo.", "seriousNumAffected": 17, "seriousNumAtRisk": 167, "otherNumAffected": 104, "otherNumAtRisk": 167}, {"id": "EG001", "title": "Lixisenatide", "description": "2-step initiation regimen of lixisenatide.", "seriousNumAffected": 46, "seriousNumAtRisk": 328, "otherNumAffected": 245, "otherNumAtRisk": 328}], "seriousEvents": [{"term": "Anogenital warts", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Coxsackie viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Incision site cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Localised infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Pharyngeal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 328}]}, {"term": "Pneumonia viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 328}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Cervix carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Glioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Lung cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Small cell lung cancer stage unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Hypoglycaemic unconsciousness", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Intercostal neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Lens dislocation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Retinal haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Retinopathy haemorrhagic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 328}]}, {"term": "Ischaemic cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Left ventricular dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Leriche syndrome", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Neuropathic ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Toxic skin eruption", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Urethral stenosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Urinary bladder polyp", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 328}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Coronary angioplasty", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Coronary arterial stent insertion", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Coronary artery bypass", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Coronary revascularisation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Victim of crime", "organSystem": "Social circumstances", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 328}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 328}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 328}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 32, "numAtRisk": 328}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 328}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 328}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 68, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 138, "numAtRisk": 328}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 328}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 328}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 328}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 328}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 37, "numAtRisk": 328}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 328}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 96, "numAtRisk": 328}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 32, "numAtRisk": 328}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 328}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 328}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 328}]}, {"term": "Blood glucose decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 328}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-us@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}